Type 2 acrodysostosis (ACRDYS2), a rare developmental skeletal dysplasia characterized by short stature, severe brachydactyly and facial dysostosis, is caused by mutations in the phosphodiesterase (PDE) 4D (PDE4D) gene. Several arguments suggest that the mutations should result in inappropriately increased PDE4D activity, however, no direct evidence supporting this hypothesis has been presented, and the functional consequences of the mutations remain unclear. We evaluated the impact of four different PDE4D mutations causing ACRDYS2 located in different functional domains on the activity of PDE4D3 expressed in Chinese hamster ovary cells. Three independent approaches were used: the direct measurement of PDE activity in cell lysates, the evaluation of intracellular cAMP levels using an EPAC-based (exchange factor directly activated by cAMP) bioluminescence resonance energy transfer sensor , and the assessment of PDE4D3 activation based on electrophoretic mobility. Our findings indicate that PDE4D3s carrying the ACRDYS2 mutations are more easily activated by protein kinase A-induced phosphorylation than WT PDE4D3. This occurs over a wide range of intracellular cAMP concentrations, including basal conditions, and result in increased hydrolytic activity. Our results provide new information concerning the mechanism whereby the mutations identified in the ACRDYS2 dysregulate PDE4D activity, and give insights into rare diseases involving the cAMP signaling pathway. These findings may offer new perspectives into the selection of specific PDE inhibitors and possible therapeutic intervention for these patients. † These authors contributed equally to the work.
Introduction
Acrodysostosis refers to a group of rare developmental skeletal dysplasias whose features include short stature, severe brachydactyly, facial dysostosis, nasal hypoplasia, and varying degrees of cognitive disability (1, 2) . Two forms of acrodysostosis are now recognized, type 1 acrodysostosis (ACRDYS1, OMIM 101800) and type 2 acrodysostosis (ACRDYS2, OMIM 614613), which are caused, respectively, by heterozygous mutations in the genes coding for the cAMP-dependent protein kinase type 1a regulatory subunit protein (PRKAR1A) and phosphodiesterase (PDE) 4D (3) (4) (5) (6) (7) . While many of the clinical features are similar in the two forms of acrodysostosis, some differences have been noted (3) (4) (5) (6) (8) (9) (10) (11) (12) (13) (14) (15) . For example, evidence of resistance to hormones binding G-protein coupled receptors (GPCR) that signal through the stimulatory G-protein alpha subunit (Gsa), and which activate protein kinase A (PKA) as part of their downstream actions [e.g. parathyroid hormone (PTH) and thyroid stimulating hormone (TSH)], is commonly present in ACRDYS1, but is more unusual in ACRDYS2 (5, 7, 12, 14) . Similarly, short stature and cone-shaped epiphyses have been noted more frequently in ACRDYS1, whereas intellectual disabilities and impaired pubertal growth appear to be more common in ACRDYS2. Nevertheless, because of the overlap between the two syndromes and the variability seen in patients carrying the same causative mutation (14, 15) , clinical features permitting the specific distinction of the two acrodysostosis syndromes have not been identified.
Phosphodiesterase (PDE) 4D (PDE4D), the gene implicated in ACRDYS2, belongs to the PDE4 family of genes. These genes code for phosphodiesterases that are highly selective for cAMP over cGMP, and account for most of the cAMP-hydrolyzing activity of most cells (16) (17) (18) (19) . By using alternative promoters/start sites and splicing, transcription of the PDE4D gene results in the expression of nine isoforms in humans, each with a distinct Nterminal sequence (17) (18) (19) . All the six 'long' forms contain two upstream conserved regions (UCR1 and UCR2) located N-terminal to the catalytic domain. The protein forms a homodimer through a dimerization domain formed by antiparallel interaction of residues in UCR1 and UCR2 of each monomer with residues in the same region of its partner (20) (21) (22) (23) . Residues in UCR1 and UCR2 also interact with the catalytic domain of the other monomer, respectively tethering the dimerization domain to the catalytic unit and forming an autoinhibitory domain that partially occludes the catalytic site (22) .
The molecular basis for the abnormalities seen in ACRDYS2 remains unclear. Several arguments suggest that the mutations would be expected to result in inappropriately increased PDE4D activity. First, in ACRDYS1 and several other syndromes associated with similar skeletal abnormalities [pseudohypoparathyroidism type 1a (PHP1A, OMIM 103580), caused by mutations that inactivate Gsa, and brachydactyly type E (BDE) with hypertension (OMIM 112410), caused by mutations that activate PDE3A] the causative mutations impair hormone signaling through the GPCR/Gsa/adenyl cyclase/cAMP/PKA pathway (24) (25) (26) (27) . In these situations, the skeletal abnormalities are thought to result from impaired signaling initiated by parathyroid hormone-related protein (PTHrP), a ligand that like PTH binds the parathyroid hormone 1 receptor (PTH1R) and uses Gsa/adenyl cyclase/cAMP/PKA as a major signaling pathway (24, 28) . The presence of similar skeletal abnormalities in ACRDYS2 supports the idea that during development, signaling by PTHrP is also attenuated, and would presuppose that the mutations in PDE4D result in inappropriately increased activity.
Second, it is known all long PDE4 isoforms, including those coded by PDE4D, are activated by PKA-induced phosphorylation at a conserved serine residue within a RRESF motif on UCR1 (23, 29, 30) . Based on the location of PDE4D mutations occurring in ACRDYS2 mapped on the PDE4B crystal structure, it has been suggested that these mutations are likely to affect the regulation of PDE4D by PKA (22) . In contrast, mutations that would inactivate PDE4D (e.g. nonsensense mutations, deletions, or mutations disrupting the catalytic site) have not been described in ACRDYS2. Indeed, mutations that result in haploinsufficiency of PDE4D (Chromosome 5q12 deletion syndrome, OMIM 615668) cause skeletal abnormalities that are the mirror-image of those seen ACRDYS2 (12, 31) .
Although these findings are consistent with the idea that mutations causing ACRDYS2 result in inappropriately increased activity, currently there is no direct evidence supporting this hypothesis. Indeed, it has been reported that PDE4D mutations causing ACRDYS2 impaired PDE4D activity, and these authors suggested that the ACRDYS2 phenotype resulted from an overcompensatory increased expression of other PDE4 isoforms (11) .
In this study, we have evaluated the impact of four different PDE4D mutations causing ACRDYS2 on the activity of PDE4D3, a long PDE4D isoform with wide tissular expression. The four mutations are localized in different functional domains, two in UCR1 (S54A, affecting the serine in the RRESF motif targeted by PKA phosphorylation, and A91S), one in UCR2 (L176V), and one in the catalytic domain (E454A). Three independent approaches were used: the direct measurement of PDE activity in cell lysates, the evaluation of intracellular cAMP levels using an EPAC-based (exchange protein directly activated by cAMP) bioluminescence resonance energy transfer (BRET) sensor, and the assessment of PDE4D3 activation based on electrophoretic mobility. Our findings indicate that PDE4D3 carrying the ACRDYS2 mutations (ACRDYS2 PDE4D3 mutants) are more easily activated by PKA-induced phosphorylation than WT PDE4D3 over a wide range of intracellular cAMP concentrations, which results in a higher activity, including under basal conditions. Our results provide new information concerning the mechanism whereby the mutations identified in ACRDYS2 dysregulate PDE4D activity, and may offer new perspectives into the selection of specific inhibitors and possible therapeutic intervention for these patients.
Results

Direct evaluation of PDE4 activity
We directly compared the activity of WT PDE4D3 with that of PDE4D3 variants carrying one of four different single amino acid substitutions (S54A, E454A, A91S, L176V) identified in ACRDYS2 patients (hereafter referred to as PDE4D mutants) ( Table 1) . To do so, PDE activity in the presence and absence of the PDE4 inhibitor rolipram (32,33) was measured as described in the methods using a two-step radioassay (34, 35) in cytoplasmic extracts prepared from Chinese hamster ovary cells (CHO) cells transfected with plasmids allowing the expression of the WT and mutant PDE4D3 isoforms. PDE4 activity in cells transfected with the empty expression vector was only 1.9 6 0.8% (mean 6 SEM, n ¼ 8) that of cells transfected with WT PDE4D3. This result is consistent with the previously reported finding that CHO cells have low PDE4 activity (36, 37) . This low endogenous activity was subtracted from the results, which therefore represent only PDE4D3 activity expressed from the plasmids.
As shown in Figure 1 , PDE4D3 activity normalized per amount of PDE4D3 protein was significantly increased in all cases in extracts from cells expressing PDE4D3 mutants compared to that of extracts from cells expressing WT PDE4D3 (mean increase in activity over WT: S54A, 89.7%; E454A, 51.8%; A91S, 95.4%; L176V, 104.7%). Thus, increases in activity were observed with the four different ACRDYS2 mutations occurring in the different functional domains of the protein.
Effect of PDE4D3 carrying ACRDYS2 mutations and WT PDE4D3 on intracellular cAMP levels
To compare the ability of mutant and WT PDE4D3 proteins to modulate intracellular cAMP, we co-transfected CHO cells with plasmids inducing the expression of PDE4D3 and a plasmid inducing expression of the YFP-Epac-RLuc cAMP BRET sensor (CAMYEL). The Rluc/YFP ratio was determined before and at regular intervals after the addition of 8-Br-cAMP to the extracellular medium of the cell suspensions. The dynamic range of the CAMYEL sensor was first determined by co-transfecting CHO cells with the CAMYEL vector and the empty expression vector (pcDNA), and incubating the cells with serial dilutions of 8-BrcAMP. As shown in Figure 2 , mBRET values between approximately 50 and 250 units were within the dynamic range of this sensor, but following exposure of cells to >5 mM 8-Br-cAMP, the mBRET values reached a plateau. Addition of 25mM rolipram had no significant effect on the signal, confirming that CHO cells express very low levels of rolipram-sensitive phosphodiesterases (36, 37) .
When cells transfected with the empty vector were incubated in the presence of 1 mM 8-Br-cAMP, mBRET levels increased progressively over the first 30 min, reaching a plateau near 200 mBRET units (Fig. 3A) . When cells transfected with vectors inducing the expression of either WT or mutant PDE4D3s were evaluated, mBRET levels increased over the first 10 min, but reached a substantially lower plateau (50-75 mBRET units), within the range of that observed in cells transfected with the empty vector and incubated in the presence of 0.1 mM cAMP (Fig. 2) . This indicates that PDE4D3 was actively hydrolyzing cAMP.
To quantify the ability of WT and mutant PDE4D3s to reduce intracellular cAMP, we calculated the area under the time curve (AUC) for the two time intervals indicated in Figure 3A , corresponding to the initial upslope in mBRET (0-10 min) and the plateau phase (20-30 min) . During the first 10 min following exposure to extracellular 8-Br-cAMP, the AUC, which reflects intracellular cAMP levels, was significantly higher in cells expressing WT PDE4D3 than in cells expressing PDE4D3 with any of the four ACRDYS2 mutations tested (Fig. 3B) , indicating that four mutant PDE4D3s hydrolyzed more cAMP than WT PDE4D3. During the plateau phase (20-30 min), the mean AUC for cells expressing WT PDE4D3 remained higher than that of cells expressing mutant PDE4D3s, differences that were still significant or approached significance in each case. Although the mean AUC for cells expressing the mutant proteins was lower than that of cells expressing WT PDE4D3 at both time points, the difference decreased with time (% reduction in AUC compared to that of WT at 0-10 and 20-30 min: S54A, 25%!15%; E454A, 12%!8%; A91S, 16%!15%, L176V, 19%!13%). These findings are compatible with the possibility that rising intracellular cAMP levels activated both WT and mutant PDE4D3s, but the extent of activation of the WT enzyme was greater than that of the mutants. When cells were exposed to 5 mM 8-Br-cAMP, the responses shared similarities with those observed in cells exposed to 1 mM 8-Br-cAMP, but several noteworthy differences were also observed (Fig. 4) . For cells transfected with the empty vector, mBRET levels increased rapidly, reaching a plateau within less than 10 min at approximately 250 mBRET. However, as shown in Figure 2 , these levels of mBRET reflect the saturation of the CAMYEL sensor, explaining this rapidly occurring plateau. Strikingly, when cells transfected with vectors inducing the expression of PDE4D3 were evaluated, mBRET levels showed a rapid initial increase, but then fell progressively, approaching a lower plateau at 20-30 min (Fig. 4A ). For cells expressing WT PDE4D3, the average peak mBRET value was 191 6 45 units (mean 6 SD, n ¼ 10), while the average mBRET value between 20-30 min was 111 6 45 units (P < 0.001 by paired t-test). A similar pattern was always seen for cells expressing the mutant PDE4D3s. In contrast, a fall in mBRET values after an initial rise was not observed when cells expressing WT or mutant PDE4D3s were exposed to 5 mM 8-Br-cAMP in the presence of rolipram, confirming that PDE4 activity was responsible for the decline (data not shown). Since a fall in mBRET at later times also did not occur in cells transfected with the empty vector ( Fig. 4A ), PDE4 activity intrinsic to the CHO cell line was not implicated. Thus, these findings clearly demonstrate that both the WT and mutant PDE4D3s are activated by increases in intracellular cAMP.
As was observed for cells exposed to 1 mM 8-Br-cAMP, during the first 10 min following exposure to 5mM 8-Br-cAMP, the AUC in cells expressing WT PDE4D3 was greater than that observed for cells expressing PDE4D3 with ACRDYS2 mutations (Fig. 4B ). During the plateau phase (20-30 min), the mean AUC for cells expressing WT PDE4D3 remained somewhat higher than that of cells expressing PDE4D3 with ACRDYS2 mutations, but the differences were small, and were not statistically significant for 3 of the 4 mutants (% reduction in AUC compared to that of WT at 0-10 and 20-30 min: S54A, 15%!8%; E454A, 15%!6%; A91S, 21%!14%, L176V, 11%!2%).
In summary, studies evaluating intracellular cAMP in cells expressing PDE4D3 demonstrate that: i) PDE4D3 could strongly reduce intracellular cAMP levels, ii) immediately following exposure to 8-Br-cAMP, the basal activity of all four mutant PDE4D3s was greater than that of WT PDE4D; iii) increases in intracellular cAMP led to further activation of both WT and the four mutant PDE4D3s, but the WT enzyme was activated to a greater extent, and its total activity began to approach that of the mutant enzymes.
Effect of pretreatment with H89 on the activation of PDE4D3 following exposure of cells to 8-Br-cAMP
The results shown in the previous section indicate that exposure to cAMP activated PDE4D3. Activation of WT PDE4D3 is known to depend on the phosphorylation of two serine residues (S13 and S54) in the N-terminal domain by PKA (29, 30, (38) (39) (40) (41) . To determine the extent that WT and mutant PDE4D3s were being activated through this mechanism, we exposed cells co-expressing PDE4D3 and the CAMYEL cAMP sensor to 1 mM 8-Br-cAMP, and used BRET to compare intracellular cAMP levels in cells that had been pre-treated with the PKA inhibitor H89 or vehicle alone (DMSO) (see examples for WT and one mutant in Fig. 5A ). The AUC (0-35 min) was determined for each curve, and results were expressed as the % change in AUC observed in H89-treated cells compared to that of the DMSO-treated cells (Fig. 5B) .
The inhibition of PKA by H89 resulted in a 35.5 6 4.5% (mean 6 SEM, n ¼ 11) increase in AUC in cells expressing WT PDE4D3, but no significant change (1.3 6 3.5% increase, n ¼ 7) in AUC in cells transfected with the empty pcDNA vector (Fig. 5B ). This ability of H89 to increase cAMP levels only in cells expressing PDE4D3 is consistent with previous studies indicating that a rise in intracellular cAMP results in activation of PKA, which in turn, activates PDE4D, thereby attenuating the increase in cAMP. As shown in Figure 5B , the inhibition of H89 also resulted in an increase in intracellular cAMP levels in cells expressing the PDE4D3 mutants (S54A, 15.4 6 5.1%; E454A, 4.0 6 2.4%; A91S, 15.7 6 6.0; L176V, 13.8 6 5.0%; n ¼ 5-6), but the extent of this increase was less than that observed for cells expressing WT PDE4D3 in each case (P < 0.05 for all comparisons by Dunnett's multiple comparison test using unpaired data).
These findings indicate that the rapid activation of both WT PDE4D3 and PDE4D3 expressing ACRDYS2 mutations observed after exposure to cells to 8-Br-cAMP is dependent, at least in part, on PKA activity. Consistent with our observation that following exposure of cells to 1 mM cAMP, the activity of WT PDE4D3 increases to a greater extent than that of the mutant PDE4D3s, the extent of PKA-mediated activation was blocked by H89 was greater for WT than for the mutant PDE4D3s under these conditions.
Comparison of the activation of PDE4D3 carrying ACRDYS2 mutations and WT PDE4D3
The results obtained evaluating their effects on intracellular cAMP levels supported the conclusion that under basal conditions the four mutant PDE4D3s were activated to a greater extent than WT PDE4D3, and while both WT and mutant PDE4D3s could be activated further following incubation of the cells with cAMP, the activity of the WT enzyme remained lower than that of the mutants until exposed to high concentrations of cAMP. To directly confirm this interpretation, we took advantage of prior observations demonstrating that activated PDE4D3 could be distinguished from the unactivated enzyme by differences in their mobility in SDS-acrylamide gels (29, 30, 40, 42) .
As shown in Figure 6 , WT PDE4D3 from untreated cells migrated predominantly as a single band with an apparent MW of 93kD, although a faint band with slower migration was visible in some blots and could be invariably quantified by immunoluminescence. For WT PDE4D from cells incubated in the presence of 1 mM 8-Br-cAMP, the intensity of the two bands was nearly equivalent, while the intensity of the upper band (corresponding to activated enzyme) from cells incubated with 1 mM 8-Br-cAMP and 25 mM rolipram was most prominent. Strikingly, for the four mutant PDE4D3s, the proportion of the upper (activated) band was considerably increased relative to that of WT PDE4D3 under basal conditions and in the presence of 1 mM cAMP (Fig. 6) . Incubation of cells expressing mutant PDE4D3s in the presence of cAMP plus rolipram resulted in the majority of the protein migrating as an upper (activated) band to an extent similar to that observed for cells expressing WT PDE4D.
It is noteworthy that the proportion of WT PDE4D migrating as the upper (activated) band increased by 82% when cells were incubated with 1 mM cAMP, whereas it only increased by 19.7% (A91S) to 30.1% (S54A) for PDE4D3 mutants. Nevertheless, the proportion of activated enzyme remained higher for mutant PDE4D3s than that of WT PDE4D3. These results recapitulate the findings based on the analysis of intracellular cAMP levels.
The reduced migration of activated WT PDE4D3 is thought to reflect conformational changes induced by PKA-induced phosphorylation (29, 30, (38) (39) (40) (41) . We confirmed that dephosphorylation of both WT PDE4D3 and mutant PDE4D3 by alkaline phosphatase substantially reduced the proportion of PDE4D3 migrating in the upper (activated) band (Fig. 7) . In addition, preincubation of cells expressing either WT and mutant enzymes in the presence of H89 for 60 min prior to exposure to 1 mM 8-Br-cAMP reduced the proportion of enzyme migrating in the upper band (data not shown).
Taken together these results demonstrate by independent techniques that: i) in cells maintained under basal conditions, the proportion of activated PDE4D3 is increased comparing cells expressing PDE4D3 carrying ACRDYS2 mutations and those expressing WT PDE4D3; ii) increases in intracellular cAMP led to the rapid phosphorylation-dependent activation of both WT PDE4D3 and PDE4D3 expressing ACRDYS2 mutations; iii) following exposure to 1 mM 8-Br-cAMP, the proportion of activated WT PDE4D3 increased to a greater extent than that of PDE4D3 expressing ACRDYS2 mutations, but the total proportion of activated enzyme remained lower; iv) exposure to high concentrations of intracellular cAMP led to the activation of a high and similar proportion of both WT PDE4D3 and PDE4D3 expressing ACRDYS2 mutations.
Discussion
We used three different approaches to characterize the effect of PDE4D mutations causing ACRDYS2 on the function of this protein: the direct measurement of PDE4 activity in cell lysates, the evaluation of intracellular cAMP levels in intact cells, and the assessment of the activation of PDE4D3 based on differences in electrophoretic mobility of the activated and non-activated enzyme. Four mutations were studied, localized in the three functional domains of the enzyme. The three approaches gave highly concordant results that are summarized as follows.
In unstimulated cells, both PDE4D3 enzymatic activity and the proportion of activated PDE4D3 are increased in cells expressing mutant PDE4D3 compared to cells expressing WT PDE4D3. Thus, at early times following incubation of cells with 1 mM 8-Br-cAMP, intracellular cAMP levels increased more in cells expressing WT PDE4D3 than in those expressing the ACRDYS2 variants. The increasing cAMP levels did result in PKA-induced activation of both WT and mutant PDE4D3s, and this increase was proportionately greater for the WT enzyme. Nevertheless, the percentage of activated PDE4D3 remained higher and cAMP levels remained lower in cells expressing the mutant PDE4D3s. When larger increases in intracellular cAMP were induced (incubation with 5 mM 8-Br-cAMP or 1 mM 8-BrcAMP þ rolipram), a high proportion of both WT and mutant PDE4D3s became activated, and significant differences in cellular cAMP levels could no longer be detected in most cases.
Taken together, these data support the conclusion that the fundamental difference in the properties of WT and mutant PDE4D3s is that the enzymes carrying ACRDYS2 mutations are more easily activated by PKA-induced phosphorylation over a wide range of intracellular cAMP concentrations, including basal levels, which results in a higher hydrolyzing activity. Once the enzymes have been fully activated, the ability of WT and ACRDYS2 variants to hydrolyze cAMP is similar.
This interpretation is consistent with the localization of mutations in PDE4D causing ACRDYS2. It was initially puzzling that these mutations occurred in several different functional domains of the protein. By mapping these mutations onto the crystal structure of PDE4B, however, Cederval et al. (22) showed that except for the S54A mutation altering a residue phosphorylated by PKA (which could not be included in the crystal structure), all ACRDYS2 mutations studied were localized at the interface between the autoinhibitory domain and the catalytic domain or at the hinge region tethering the dimerization domain to the autoinhibitory and catalytic domains. Thus, the mutations are well positioned to influence the regulation of PDE activity by PKA without impairing the functional activity of the activated enzyme. The mechanism described by us is also reminiscent of the recently described effects of mutations in PDE3A causing BDE with hypertension (27) . In this case, the mutations increase PKA-mediated activation of PDE3A, resulting in increased PDE activity. However, the increased phosphorylation of PDE3A was found to decrease the K m for cAMP without changing the V max , whereas phosphorylation of PDE4D has been found to increase the V max without changing the K m for cAMP (23, 29) .
The multifarious effects of phosphorylation on PDE4D3 activity has been extensively evaluated, as summarized in several reviews (17, 19, 23) . In PDE4D3, PKA-induced phosphorylation occurs predominantly at two sites (S13 and S54), and results in a 2-to 6-fold increase in PDE activity (29, 39) . In variants carrying the S13A mutation, phosphorylation of S54 alone is sufficient to produce full activation (29) , and certain 'phosphomimetic' mutations at this position (e.g. S54D and S54E) result in constitutive activation of PDE4D3 (39) . In contrast, phosphorylation of S13 is required to produce the conformational changes that result in reduced electrophoretic mobility (30, 43) . In agreement with these studies, we found that alkaline phosphatase treatment of the PDE4D3 carrying the S54A mutation led to a decrease in the proportion of enzyme migrating in the upper (activated) band comparable to that seen for WT PDE4D3 and the other mutant PDE4D3s. Our findings indicate, however, that phosphorylation of S54 (or its replacement by a phosphomimetic mutation) is not absolutely required for PDE4D3 activation, since the S54A mutation also resulted in an enzyme more sensitive to PKA-induced activation. These observations are consistent with the possibility that S54!A substitution removes contacts postulated to reinforce the maintenance of PDE4D3 in the inactive state (39) , resulting in structural changes that facilitate the phosphorylation of S13. Consistent with this possibility, the S54A mutation has been shown to produce the conformational changes that result in higher affinity for rolipram, although the variant does not become constitutively active (39) . A recently identified S54F ACRDYS2 mutation (15) induces the same in vitro (39) and clinical (15) phenotypes observed for S54A (39) . By extension, our results suggest that other ACRDYS2 mutations may serve to weaken the interactions maintaining PDE4D3 in the inactive state, thereby facilitating phosphorylation of S54 and/or S13.
Viewed in retrospect, our findings are not incompatible with many prior studies evaluating PDE4D3 carrying the S54A mutation performed prior to its identification as an ACRDYS2 mutation. The activities of S54A and WT PDE4D3 were similar when evaluated in the absence of PKA activity (39) . Studies evaluating cells expressing PDE4D3 with the S54A mutation found that the addition of catalytic PKA to cell extracts or treatment of cells with dibutyryl cAMP resulted in only small increases in activity, but the possibility that a substantial fraction of the enzyme had been activated under basal conditions, as observed in our study, was not considered (29) . Our findings do not support the idea that PDE4D3 carrying the S54A mutation cannot undergo PKAinduced conformational changes that reduce electrophoretic mobility (30) . We did not observe that ACRDYS2 mutations impaired PDE4D3 activity, as reported by Kaname et al. for PDE4D5 (11) . Of note, we did not evaluate the same mutations studied by these authors, although several were located in close proximity to those studied by us. PDE4D can be phosphorylated by a number of other kinases, including extracellular signal-regulated kinase (ERK2) (44) (45) (46) calcium/calmodulin kinase II (47) and cyclin-dependent kinase 5 (48) . In addition to directly stimulating or inhibiting the activity of PDE4D, the action of these kinases can influence enzyme localization and conformation. Further studies would be required to determine if these effects can modulate the enhanced susceptibility to activation of PDE4D3 carrying ACRDYS2 mutations. Similarly, the comparison of the effects of ACRDYS2 mutations on the activity of different isoforms of PDE4D would be of potential interest.
Our findings support the idea that the skeletal abnormalities occurring in ACRDYS2 are caused by PDE4D mutations that increase PDE4D3 activity, thereby attenuating signaling by PTHrP through the PTHR-cAMP-PKA pathway during development. Thus, the mechanism is similar to that proposed for the skeletal dysplasia occurring in ACRDYS1 (3,8,49 ), pseudo-hypoparathyroidism type 1A (26) , and BDE with hypertension (27) .
Interestingly, resistance to hormones signaling through the GPCR-cAMP-PKA pathway (e.g. PTH and TSH) is a common occurrence in ACRDYS1 and PHP-1A (3-6,8,10,12) . In contrast, hormone resistance in ACRDYS2 is less frequently observed (4, 6, 9, 11, 12, 14) . A number of hypotheses have been raised to explain this discrepancy [reviewed in (50) ]. We have presented evidence that the intensity of the initiating hormone-dependent intracellular signal immediately following stimulation with an agonist influences the extent that PDE4D can modulate downstream events (50) . According to this model, inappropriately increased PDE4D activity could attenuate initially weak signals (resulting, for example, from exposure to low concentrations of ligand or expression by the cells of few receptors), but would have less effect on initially strong signals. The findings in the current study are consistent with this hypothesis. The greatest difference in PDE4D3 activity comparing WT and mutant PDE4D3s was observed in cells with only basal or moderately increased intracellular cAMP concentrations, giving mutant PDE4D3s an advantage in attenuating initially weak signals. Following large rises in intracellular cAMP resulting from strong stimulatory signals, both WT and mutant PDE4D3s would be activated and have comparable effects on downstream signaling. Thus, unlike mutations in PRKAR1A and GNAS responsible for ACRDYS1 and PHP-1A respectively, which impair hormone induced responses regardless of their intensity, PDE4D mutations would be expected to impair some, but not all, responses, potentially explaining the presence of acrodysostosis without hormonal resistance in ACRDYS2. Currently, however, there is no direct evidence that cAMP levels induced by PTHrP in chondrocytes during skeletal development are lower than those induced by PTH and TSH in their target tissues.
In conclusion, our results provide new information concerning the molecular pathogenesis of ACRDYS2. These observations may prove helpful for the selection of specific PDE4 inhibitors, and offer new perspectives into possible therapeutic intervention for these patients.
Materials and Methods
Nomenclature
Nine isoforms of PDE4D have been described, resulting from alternative splicing and use of distinct transcription start points in the 5'-region of the gene (16, 19) . As a result, the numbering of amino acids common to the C-terminal portion of these isoforms is different. By convention, the PDE4D4 sequence (NM_001104631; NP_001098101) is used to indicate the amino acid substitutions associated with clinical diseases. In the experiments described in this study, cells expressing PDE4D3 (NM_006203; NP_006194) were used, and all amino acids are numbered according to the sequence of this isoform. For all ACRDYS2 mutations specified in this manuscript, the numbering in the PDE4D3 and PDE4D4 isoforms is shown in Table 1 .
PDE4D mutations and patients
Four PDE4D mutations causing acrodysostosis without hormonal resistance were studied. Three of the mutations have been previously reported together with the patients' clinical, biochemical and skeletal phenotype. These include the two mutations localized in UCR1 [S190A (6) and A227S (26) ] and the mutation localized in the catalytic domain (E590A) (4, 26) . The fourth mutation, localized in UCR2 (c.934c > g, NM_001104631; p.L312V, NP_001098101) has not been previously reported. The affected woman was referred at the age of 42 years to GD for evaluation of brachydactyly with severe intellectual delay. She presented with bilateral severe brachymetacarpy and metatarsy affecting all fingers except for the proximal phalanx of the 3rd finger. Thickbodied bones were noted, but widening of the lumbar interpediculate distance and ossification were not observed. Her height was 1m39 and her weight was 76.5 kg. Initial biochemical and endocrine studies revealed normal serum calcium (2.34 mmol/l); and low normal serum phosphate (0.9 mmol/l, normal range: 1-1.5 mmol/l); increased serum PTH (107 pg/ml, normal range: 10-65); normal serum TSH (1.24 lIU/ml, normal: <5); normal LH (1,5 IU/l, normal range 0.5-5.0); increased FSH (8.3 IU/l, normal range 0.8-4.4); and low serum levels 25-OH vitamin D (13.9 ng/ml, normal range 20-100). Vitamin D supplementation led to normalization of serum PTH. The mother had neither brachydactyly nor abnormal endocrine function. Informed written consent was obtained from the patient's mother. Analysis of the GNAS locus, including sequencing of GNAS exons 1 through 13 and evaluation of methylation at the four differentially methylated regions gave normal results (data not shown), ruling out abnormalities in the expression or function of the Gsa protein coded by this locus, and no mutations were identified in the PRKAR1A gene. The L312V PDE4D variant was not seen in the mother or in 200 controls, and has not been reported in available databases (Single Nucleotide Polymorphism performance database/National Center for Biotechnology Information, 1000 genomes, exon variant servers, Human Genome Mutation Database, LOVD mutation database). Clinical information and DNA from the father were not available.
Cell culture
CHO-K1 cells (ATCC) were cultured in Ham's F12 Nutrient Mixture (ThermoFisher Scientific, Waltham, MA) supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin G and 100 mg/ml streptomycin (complete medium), and passaged on a weekly basis.
Plasmids
A plasmid containing the PDE4D3 sequence was kindly provided by M.D. Houslay (University of Glasgow, Glasgow, UK). To produce non-tagged expression vectors, the coding sequence of PDE4D3 was amplified by PCR using oligonucleotides including NotI (forward primer) and XhoI (reverse primer) restriction sites at the 5'-ends, digested with these enzymes and cloned into pcDNA3.1 (Invitrogen) (35) . To produce vectors producing hemagglutinin (HA)-tagged PDE4D3, a similar strategy was employed, using a reverse primer that removed the stop codon, and the PCR product was cloned into a vector already containing a HA tag that had been cloned between the XhoI and XbaI sites of pcDNA3.1 (35) . These vectors produced full-length PDE4D3 containing a 12 amino-acid C-terminal extension containing the HA epitope. ACRDYS2 mutations (S54A, A91S, L176V, E454A) were introduced using the QuickChange site-directed mutagenesis kit (Stratagene) according to the manufacturer's instructions. All constructions were verified by sequencing the inserts.
The YFP-Epac-RLuc cAMP BRET sensor CAMYEL plasmid has been previously described (50, 51) , and was purchased from ATCC (LGC Standard, Molsheim, France).
Measurement of phosphodiesterase activity
CHO cells were cultured in 6-well plates (3.8 Â 10 5 cells/well in 2.4 ml complete medium) for 24 h and transfected by adding drop-wise 125 ml of Opti-MEM medium (ThermoFisher Scientific, Courtaboeuf, France) containing 500 ng of plasmid DNA (either 300 ng HA-tagged PDE4D3 expression plasmid plus 200 ng empty pcDNA plasmid or 500 ng empty plasmid alone) and 9.5 ml XtremeGENE DNA HP Transfection Reagent (Roche Diagnostics, Mannheim, Germany). Forty-eight h later, cells were washed three times with cold PBS, and lysed by adding 300 ml lysis buffer A [50 mM Tris-HCl (pH 7.4) containing 150 mM NaCl, 0.5% (v/v) Nonidet-P40 (Sigma), 1 ml Halt Protease Inhibitor Cocktail (100X, ThermoFisher Scientific)]. Cells were scraped from the plate and transferred to 1.5 ml conical centrifuge tubes, and kept on ice for 10 min before centrifugation (12,000Âg; 10 min; 4 C).
Supernatants were stored at À80 C.
PDE activity was assayed using the two-step radioassay described by Marchmont and Houslay (34, 35) . Briefly, duplicate aliquots of each cell supernatant were resuspended in 100 ml of 20 mM Tris-HCl (pH 7.4) containing 5 mM MgCl 2 , 1 mM cAMP and tracer amounts of 8-[ 3 H]cAMP in the presence or absence of 10 mM of the PDE4 inhibitor rolipram (32, 33) , and incubated for 10 min at 30 C. The samples were then placed in boiling water for 2 min and cooled on ice. Twenty-five ml of 1 mg/ml snake venom (Sigma-Aldrich; #V0376) was added and incubated for 10 min at 30 C. After cooling, pre-equilibrated Dowex 1-8 resin was added, and samples incubated on ice for 15 min to bind unhydrolyzed cAMP. The tubes were centrifuged (12,000Âg; 3 min), and 150 ml aliquots of supernatant were mixed with scintillation fluid. The amount of [ 3 H]adenosine was determined using a Wallac 1409 liquid scintillation counter. The ratio of the PDE4D3 activity produced following transfection per the amount of PDE4D3 protein present in the lysate was determined as follows: PDE4 activity was determined by subtracting the activity remaining after rolipram treatment from total activity. PDE4D3 activity was determined by subtracting the PDE4 activity measured in cells transfected with the empty plasmid. These values were then divided by the amount of total PDE4D3 protein in the lysate, which was determined by Western blotting as described below. For each experiment, values were expressed relative to that of WT PDE4D3, which was assigned the value of 100%.
Evaluation of intracellular cAMP using a bioluminescence resonance energy transfer (BRET) sensor CHO cells were cultured at 8Â10 4 cells/well (24-well plates) in 0.5 ml complete medium. Twenty-four hours later, 25 ml of Opti-MEM medium containing 200 or 300 ng of PDE4D3 expression plasmid (carrying the WT or one of the four mutant sequences) and, respectively, 300 or 200 ng empty vector (pcDNA) or 500 ng empty vector alone; 150 ng of the YFP-Epac-RLuc cAMP BRET sensor (CAMYEL) plasmid; and 2 ml X-tremeGENE HP DNA Transfection Reagent) was added drop-wise to each well. Duplicate or triplicate wells were prepared for each condition. Forty-eight hours later, cells were washed with calcium/ magnesium-free PBS, trypsinized, and replicate wells were pooled, after which cells were washed again and resuspended in PBS containing calcium/magnesium. Ninety ml aliquots of the cell suspensions (1Â10 4 cells/well) were plated in white flatbottomed 96-well microtiter plates; 10 ml of a 50 mM solution of Coelenterazine-h was added to each well, and the plates were incubated for 10 min at 37 C. Cells were then treated with the indicated concentrations of 8-Br-cAMP, rolipram and/or H89. The BRET ratios were obtained by measuring simultaneously the emission at 460 nm (Renilla luciferase, Rluc) and 535 nm (YFP) using a Mithras LB940 plate reader (Berthold Technologies) (3, 49) . Measurements were made prior to adding 8-Br cAMP and at regular intervals after its addition, beginning at 2 min. The Rluc/YFP ratios were determined and converted to the corresponding milli-BRET (mBRET) values as described by Achour et al. (52) . Binding of cAMP to the Epac domain of the CAMYEL vector reduces the YFP signal. Thus, increasing mBRET values indicate increasing intracellular cAMP levels.
Direct comparison of cells expressing tagged and untagged WT and mutant PDE4D3s demonstrated that the C-terminal epitope tag did not change enzyme activity or expression (data not shown), results consistent with previous studies (16, 39, 53) . Quantification of the PDE4D3/actin ratio by Western blotting, as described below indicated that the expression of WT and mutant PDE4D3s were similar (data not shown).
Evaluation of the effect of activation and dephosphorylation on the mobility of PDE4D3 in SDS gels CHO cells were cultured in 24-well plates (8 Â 10 4 cells/well in 500 ml complete medium) for 24 h and transfected as described above using 25 ml of Opti-MEM medium containing 300 ng of HAtagged PDE4D3 expression plasmids and 2 ml X-tremeGENE HP DNA Transfection Reagent. Ten wells each were transfected with WT or one of the four mutant sequences. Forty-eight hours later, cells were rinsed twice with PBS, 100 ml PBS containing 1 mM 8-Br-cAMP, 25 mM Rolipram, or PBS alone was each added to half the wells and cultures were incubated at 37 C with shaking for 20 min. Cells were then lysed as described above, and lysates from replicate wells pooled in 1.5 ml microfuge tubes were stored at À80 C.
To immunoprecipitate PDE4D3, lysates were thawed on ice, resuspended, and incubated on ice with 1 mg of rat anti-HA monoclonal antibody (clone 3F10; Roche, Sigma-Aldrich). Forty ml of Protein G sepharose 4 Fast Flow (GE Healthcare Life Sciences) pre-equilibrated with lysis buffer A was added and incubated on a tube rotator at 4 C for 1h. Beads were collected by centrifugation (12,000Âg; 1 min), washed three times with lysis buffer A, resuspended in lysis buffer A and stored at À80 C until further use.
In some experiments, immunoprecipitated proteins were treated with alkaline phosphatase as follows. Sepharose beads with adherent immunoprecipitated proteins were thawed on ice, resuspended in buffer A, divided into two equal aliquots, centrifuged, and the supernatant was removed. Fifteen ml of 1X lysis buffer B [62.5 mM Tris-HCl (pH 7) containing 0.1% (w/v) SDS, 4% b-mercaptoethanol, 8% (v/v) glycerol, 4 mM EDTA, 4 mM EGTA, 2 mM NaF, 2 mM p-nitrophenyl phosphate (Sigma), 1 mM Na 3 VO 4 (Sigma), 0.1% (w/v) sodium azide, 2.5 mM 4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride, 2 mM sodium pyrophosphate, and Complete Inhibitor Protease (Roche; 1 tablet/ 125 ml lysis buffer)] was immediately added to one sample. The second sample was resuspended in 5 ml (10 U) of FastAP (FastAP Thermosensitive Alkaline Phosphatase, ThermoFisher Scientific) and 2 ml FastAP buffer, and incubated at 37
C for 1 h with gentle shaking. An additional 5 ml (5 U) of FastAP was added, and the incubation continued for 30 min. The reaction was stopped by adding 3 ml of 5X lysis buffer B.
Proteins were separated by electrophoresis into 12% Laemmli gels (30 mA constant current) until the pre-stained 37kD molecular weight marker (Biorad) had migrated to the bottom of the gel, and proteins were transferred to Immobilon-P membranes. Membranes were blocked by incubation for 1 h in Odyssey blocking buffer (Li-Cor Biosciences), and incubated overnight at 4 C with rabbit anti-HA IgG (Santa Cruz Biotechnology) diluted 1:500 in 50 mM Tris-HCl (pH 7.4) containing 150 mM NaCl and 0.1% Tween 20 (TBS-T). Immunodetection was performed using the SNAP i.d. system according to the manufacturer's instructions (Millipore). Briefly, membranes were washed four times with TBS-T, incubated at room temperature with horseradish-conjugated goat anti-rabbit IgG (Cell Signaling Technology; #7074) diluted 1:1000 in TBS-T, and washed four times in TBS-T. Bands were revealed using the luminol-based West Pico Chemiluminescent Substrate (Thermo Scientific). Immunofluorescence was recorded using an ImageQuant LAS-4000mini chemiluminescence imager (Fujifilm, Tokyo, Japan) and analysed using Multi-GuageV3 software (Fujifilm).
Quantification of PDE4D3 protein cell lysates by western blotting
To quantify PDE4D3 protein in cell lysates used to evaluate PDE4D3 activity, equal volumes of the same lysate were electrophoresed into SDS acrylamide gels as described above, but without immunoprecipitation. Western blotting and quantification of PDE4D3 was performed as above.
